Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
An unusual update at last month’s AAIC meeting puts the focus on a phase 2 readout next year, but time might be running out.
Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.
A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.